TrialThe Lancet. Oncology2016

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

Johan F Vansteenkiste et al.PubMed ↗Publisher ↗

No numbers read from the abstract.